{"id":"W4319460830","doi":"10.1093/bjd/ljac089","title":"Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials","year":2022,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":32,"is_retracted":false,"has_abstract":true,"ca_institutions":"Probity Medical Research; Queen's University","funders":"UCB Pharma; Manchester Biomedical Research Centre; National Institute for Health and Care Research","keywords":"Ustekinumab; Medicine; Secukinumab; Adalimumab; Psoriasis Area and Severity Index; Discontinuation; Adverse effect; Psoriasis; Dermatology; Dermatology Life Quality Index; Clinical trial; Internal medicine; Psoriatic arthritis; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006100926,0.0004224456,0.002088971,0.0004002654,0.0004793546,0.00007088016,0.0004665778,0.000367945,0.001007558],"category_scores_gemma":[0.0005185634,0.0003835199,0.0001856263,0.0003765441,0.0001203163,0.0002532806,0.0002247966,0.0007498106,0.00002003866],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000211207,"about_ca_system_score_gemma":0.0004140841,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001584328,"about_ca_topic_score_gemma":0.0009816628,"domain_scores_codex":[0.9941803,0.002322789,0.002068544,0.0006380536,0.0001991562,0.0005911719],"domain_scores_gemma":[0.9962564,0.001866704,0.001212352,0.0003343443,0.0001934608,0.0001367676],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7160042,0.004843947,0.01149393,0.00002187665,0.005081038,0.01048306,0.005814193,0.0004431741,0.001568294,0.00002969635,0.01395438,0.2302622],"study_design_scores_gemma":[0.8077281,0.004667946,0.1298425,0.0008290449,0.001843571,0.02085355,0.002244698,0.00003648723,0.008158283,0.0003488343,0.02185208,0.001594875],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9889496,0.003387494,0.0001216379,0.0005239184,0.00101045,0.0007815218,0.005126881,0.00003216614,0.00006635954],"genre_scores_gemma":[0.9972557,0.0005021853,0.0003647943,0.0002615778,0.00008698929,0.0000445855,0.001302534,0.00005076324,0.0001308654],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2286674,"threshold_uncertainty_score":0.9999056,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01907863473431349,"score_gpt":0.2518359652470177,"score_spread":0.2327573305127043,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}